HBOT Mechanics and Protocols: How Hyperbaric Oxygen Therapy Works, Session by Session

Most people hear “hyperbaric oxygen therapy” and imagine a pressurized tube, 100% oxygen, and some vague promise of accelerated healing. What they rarely get is a clear explanation of how the mechanism actually works, why pressure levels matter so much, and how protocols differ by condition. This page covers the full picture, from the physics of dissolved oxygen to the clinical protocols used for everything from wound healing to brain injury recovery.

If you are evaluating HBOT for yourself or a family member, understanding the mechanics is not optional. The pressure level, session length, number of sessions, and chamber type all determine whether you are getting a therapeutic intervention or something that looks like one on paper.

How HBOT Works: The Science of Pressurized Oxygen

At sea level, your lungs pull oxygen into the bloodstream, where hemoglobin picks it up and delivers it to tissues. This system is efficient, but it has a ceiling: hemoglobin saturates at around 98% under normal conditions. You cannot simply breathe more oxygen and get more delivery through this pathway.

Pressure changes that equation. Henry’s Law describes the relationship precisely: at higher atmospheric pressure, more gas dissolves directly into liquid. In a hyperbaric chamber breathing 100% oxygen, oxygen bypasses the hemoglobin system and dissolves directly into plasma and tissue fluid. At 2.0 ATA, tissue oxygen levels reach roughly 333 mmHg, compared to 161 mmHg at 1.4 ATA, according to research by Sack et al. published in 2023. That is not a marginal difference. It means oxygen reaches tissues that damaged blood vessels cannot supply through normal circulation.

This dissolved oxygen drives several downstream effects that researchers believe account for HBOT’s clinical benefits:

• Angiogenesis: New blood vessel formation, triggered by cycles of high oxygen followed by relative normal oxygen between sessions.
• Anti-inflammatory signaling: Suppression of pro-inflammatory cytokines and neutrophil adhesion.
• Stem cell mobilization: Eight-fold increase in circulating stem cells after 20 sessions, as documented in research published by Thom et al. in the American Journal of Physiology.
• Bacteriostatic effect: High tissue oxygen is toxic to anaerobic bacteria, which is why HBOT works for necrotizing infections and osteomyelitis.
• Mitochondrial support: Enhanced ATP production in oxygen-starved tissues, relevant to conditions involving mitochondrial dysfunction.

To understand HBOT properly, you can start with the foundational overview of what HBOT is and how it’s used clinically. The mechanics described here build on that foundation.

The critical point is that these effects are pressure-dependent. Low-pressure sessions without 100% oxygen do not reliably trigger the same cascades. This is why the choice of chamber and protocol is not a minor detail.

Pressure Levels Explained: 1.3 to 3.0 ATA

ATA stands for atmospheres absolute, a unit of pressure where 1.0 ATA equals sea level pressure. Every increment above 1.0 ATA represents one additional atmosphere of pressure added to the baseline.

Here is how the major clinical pressure levels compare, and what they mean in practice:

The Undersea and Hyperbaric Medical Society (UHMS) sets 1.4 ATA as the minimum pressure for any recognized clinical indication. Sessions below that threshold do not qualify as hyperbaric therapy under their standards. This matters especially when evaluating home chambers or wellness centers that use soft chambers at 1.3 ATA.

Soft Chambers vs Hard Chambers: What the Evidence Says

The distinction between chamber types is arguably the most misunderstood topic in HBOT. The marketing around soft chambers is often misleading, and patients deserve a clear account of what the evidence actually shows.

Soft Chambers (1.3 ATA)

Soft chambers are portable, inflatable units that pressurize to approximately 1.3 ATA using ambient air. Some allow an oxygen concentrator to be added inside the chamber. They are widely available for home purchase and marketed aggressively for wellness, anti-aging, and off-label recovery purposes.

The clinical problem is straightforward. Research by Burman et al. (2019) established that breathing ambient air at 1.3 ATA delivers a partial pressure of oxygen equivalent to breathing an oxygen mask at sea level. There is essentially no meaningful pressure advantage over simply using supplemental oxygen without a chamber.

Adding an oxygen concentrator inside a soft chamber improves oxygen delivery somewhat, but still falls far short of the tissue saturation achieved in a hard chamber at 2.0 ATA breathing 100% oxygen. No UHMS-recognized indication is approved at 1.3 ATA, and no peer-reviewed clinical trial has demonstrated therapeutic efficacy for any condition at that pressure level using the soft chamber design.

This does not mean soft chambers produce no effect. Some users report benefits, and there may be mechanisms not fully understood. But the evidence base that supports HBOT for wound healing, radiation injuries, brain conditions, and infection control was built almost entirely on hard chamber protocols at 1.5 ATA or higher. If you are evaluating a home hyperbaric chamber, understanding these limitations is essential before spending thousands of dollars.

Hard Chambers (1.5 to 3.0 ATA)

Hard chambers are rigid vessels, either monoplace (single patient) or multiplace (several patients treated simultaneously, using masks or hoods to deliver 100% oxygen). They can reach therapeutic pressures of 1.5 to 3.0 ATA and are the only chamber type used in clinical trials underlying UHMS-approved indications.

At 2.0 ATA breathing 100% oxygen in a hard chamber, tissue oxygen reaches 333 mmHg. At 2.4 ATA, plasma oxygen saturation is high enough to sustain life in animal models even without functional hemoglobin, which illustrates how dramatically dissolved oxygen differs from what the body achieves through normal respiration.

Hard chambers require a clinical facility, trained staff, and safety protocols. They are not appropriate for unsupervised home use.

Standard Session Protocols by Condition

There is no single universal HBOT protocol. Pressure, session duration, total number of sessions, and frequency are all adjusted based on the condition being treated, the patient’s response, and available evidence. Below is a reference table for the most common clinical protocols.

These protocols are established by clinical consensus, UHMS guidelines, and the evidence base from randomized trials. Individual clinics may deviate from these ranges, which is why verifying a clinic’s approach before committing to a protocol matters. The process for vetting an HBOT clinic covers what questions to ask and what answers should raise flags.

For detailed condition-specific information, the chronic conditions HBOT hub covers the evidence base across a range of long-term diagnoses.

The 40-Hour Protocol

The 40-hour protocol has become a de facto standard for neurological and chronic conditions, though it is not a single rigid template. The name refers to 40 sessions of 60 minutes each, typically delivered over 8 weeks at a rate of 5 sessions per week with 2 rest days.

Why 40 sessions? The biological rationale is built around the time required for angiogenesis to produce measurable clinical benefit. New blood vessel formation takes weeks, not days. The intermittent hyperoxia pattern created by repeated sessions appears to be more stimulating to vascular growth than continuous high-dose oxygen, which is one reason protocols include rest days rather than daily sessions.

Some protocols extend to 60 sessions or more, particularly for anti-aging applications. The landmark research on telomere lengthening and senescent cell clearance by Efrati and colleagues at Tel Aviv University used 60 sessions at 2.0 ATA over 90-minute periods, with short air breaks built into each session to maximize the hyperoxia-normoxia cycling effect.

For urgent or severe conditions, accelerated “doubles” protocols are sometimes used: two sessions per day with a minimum 4-hour break between sessions. This approach is most common for necrotizing infections and some wound healing situations where faster tissue response is needed. Doubles require careful monitoring because cumulative oxygen exposure increases adverse event risk.

A useful point for patients to understand: the benefits of HBOT often emerge gradually and sometimes peak several weeks after the final session, as angiogenesis and stem cell activity continue working after treatment ends. This is different from medications that wear off between doses. Patients who feel modest improvement mid-protocol sometimes experience significant benefit weeks after completing their course.

Why More Pressure Is Not Always Better

The intuitive assumption is that higher pressure delivers more oxygen, which means better outcomes. The clinical data does not support this assumption as a general rule.

The most striking evidence comes from traumatic brain injury research. A 2022 study by Harch and colleagues directly compared 1.5 ATA and 2.4 ATA protocols for mild TBI and post-concussion syndrome. The 1.5 ATA group showed significantly better outcomes on neurological measures. The higher pressure not only failed to improve results, it produced worse ones. The researchers concluded that at 2.4 ATA, excess oxygen may trigger reactive oxygen species (free radicals) that partially offset the therapeutic benefit, particularly in the sensitive neural environment of the recovering brain.

Similar findings appear in radiation cystitis research. Studies comparing 2.0 ATA and 2.4 ATA protocols for radiation-induced bladder damage found similar efficacy at both pressures, with no meaningful advantage to the higher dose. Given that adverse events increase with pressure, the lower setting offers a better risk-benefit ratio.

The pattern across the literature suggests that optimal pressure is condition-specific and that there is likely a therapeutic window for each application, below which the mechanism does not fully activate, and above which toxicity and diminishing returns emerge. This is not unique to HBOT. It mirrors the dose-response curves seen in pharmacology: there is a therapeutic range, and exceeding it is not neutral.

What this means practically: a clinic defaulting to 2.4 ATA for every patient and every condition may not be optimizing your protocol. Asking specifically why a pressure level was chosen, and what the evidence shows for your condition at that pressure, is a reasonable and important question.

For conditions involving the brain and nervous system, where the 1.5 ATA finding is most clinically relevant, the brain conditions HBOT hub covers the evidence across TBI, stroke, post-concussion syndrome, and related diagnoses.

Side Effects by Pressure Level

HBOT has a strong safety profile under clinical conditions, but adverse events do occur. Understanding the risk profile by pressure level helps patients have more informed conversations with their providers.

At 1.45 ATA

A 2023 study by Monge and colleagues found a 7.1% adverse event rate per session at 1.45 ATA. All events were classified as subjective barotrauma: ear pain, sinus discomfort, and pressure sensation. No serious adverse events were recorded at this pressure level across the study population.

At Higher Pressures (2.0 ATA and Above)

A 2024 review by Laspro and colleagues reported the following adverse event rates at higher clinical pressures:

• Myopia (temporary vision changes): 24.4%
• Barotrauma (ear or sinus): 14.9%
• Confinement anxiety: 11.5%
• Oxygen toxicity seizure: rare, less than 0.003% per session in properly screened patients

The myopia finding is important to understand correctly. The temporary vision changes that develop during HBOT treatment generally reverse within 6 to 8 weeks after completing a course of therapy. They are caused by changes in the lens, not permanent retinal damage. However, patients with pre-existing cataracts or lens implants should discuss this with their provider before starting treatment.

Adverse events increase above 2.0 ATA and again after cumulative session counts exceed 10. This is one reason protocols build in regular review points and why some conditions are treated at lower pressures when the evidence supports it.

The complete guide to HBOT side effects covers each adverse event type in detail, including who is at elevated risk and which contraindications are absolute versus relative.

The Mayo Clinic’s HBOT overview also provides a patient-accessible summary of risks and contraindications that is worth reviewing before beginning treatment.

What a Typical HBOT Session Looks Like

For patients who have never experienced HBOT, the clinical reality is often different from what they imagine. Here is an honest account of what to expect, from arrival through recovery.

Before the Session

You will typically be asked to avoid alcohol and carbonated drinks in the hours before treatment, as these can affect pressure tolerance. You will change into 100% cotton clothing provided by the facility. Synthetic fabrics, hairsprays, perfumes, and petroleum-based skin products are prohibited because they can create fire risk or outgas contaminants in the pressurized oxygen environment.

A brief clinical review covers any symptoms since your last session, particularly ear pain, sinus congestion, or cold symptoms. Active upper respiratory infections are a temporary contraindication because pressure equalization becomes difficult and painful.

Pressurization (Compression Phase)

The session begins with pressurization, which typically takes 10 to 15 minutes to reach treatment pressure. During this phase, you will feel a sensation similar to descending in an airplane. Ear equalization is the main patient task: yawning, swallowing, or performing a Valsalva maneuver (gently holding your nose and blowing) to open the Eustachian tubes.

Patients who have difficulty with ear equalization are sometimes given a decongestant before sessions or referred for tympanostomy tubes in cases where chronic equalization failure would otherwise prevent treatment.

At Pressure (Treatment Phase)

Once at treatment pressure, you breathe 100% oxygen continuously (in monoplace chambers) or through a mask or hood (in multiplace chambers). The treatment phase is 60 to 120 minutes depending on your protocol. Most patients read, watch a screen, or sleep. Some experience mild warmth as the pressure increases the ambient temperature slightly. The environment is quiet, and the sensation at full pressure is generally unremarkable.

In protocols that use air breaks, you will briefly breathe normal air through a mask for 5 minutes every 20 to 30 minutes. These breaks reduce the risk of oxygen toxicity and enhance the hyperoxia-normoxia cycling effect that drives some of the angiogenic benefits.

Depressurization (Ascent Phase)

Depressurization takes 10 to 15 minutes and must be gradual to allow gases dissolved in tissue to safely off-gas. Ascending too quickly would be equivalent to a diver ascending too fast: bubble formation in the bloodstream. Properly managed decompression rates make this a controlled, comfortable process.

After the Session

Most patients feel normal or slightly tired immediately after. Some report heightened energy or mental clarity in the hours following. Fatigue is more common in the first several sessions as the body adapts to the treatment cycle. Significant post-session fatigue should always be reported to the clinical team.

Understanding what you are paying for, what the costs typically look like, and how insurance interacts with HBOT is covered in detail in the guide to finding and paying for HBOT.

The Bottom Line

HBOT is not a single therapy. It is a family of protocols that differ meaningfully in pressure, duration, session count, and chamber type, each producing different clinical outcomes for different conditions.

The core mechanism is well-established: dissolved plasma oxygen at supraphysiological concentrations reaching tissues that hemoglobin-delivered oxygen cannot access. The downstream effects, from angiogenesis to stem cell mobilization to anti-inflammatory signaling, are real and documented. But they depend on reaching therapeutic pressure levels, and on matching the protocol to the condition.

The most important practical conclusions from the evidence:

• Soft chambers at 1.3 ATA do not deliver therapeutic hyperbaric oxygen by any evidence-based definition.
• 1.5 ATA is the clinical minimum for UHMS-recognized indications, and for some brain conditions it outperforms higher pressures.
• The 40-session, 8-week format is the standard for chronic and neurological conditions, with benefits sometimes continuing to accumulate weeks after the final session.
• Adverse events increase above 2.0 ATA and after 10 cumulative sessions. More pressure is not inherently safer or more effective.
• The right protocol depends on your specific condition, not on what a facility defaults to.

Anyone considering HBOT should verify that the facility uses a hard chamber capable of reaching at least 1.5 ATA, that the protocol proposed is matched to the evidence for their condition, and that the clinical team can explain why specific pressure and session parameters were chosen.